China’s NMPA accepts Innovent application for sintilimab combo
Innovent Biologics has received acceptance from China's National Medical Products Administration (NMPA) to review its sintilimab and Nolgileucel injection (GC101)…
All articles by Salong Debbarma
Salong Debbarma
-
-
Lunit and Summit to evaluate pathology platform for tumour analysis
Lunit and Summit Therapeutics have entered a research agreement to assess the Lunit SCOPE IO AI pathology platform for analysing…
-
Pathos AI completes $237m Series E round to expand oncology pipeline
Pathos AI has secured $237m in a Series E financing round to expand its clinical oncology pipeline and scale its…
-
Boehringer and Microsoft collaborate to explore AI in clinical research
Boehringer Ingelheim and Microsoft have entered a strategic collaboration to examine the use of AI in clinical research, beginning with…
-
Celltrion and Kaigene sign $580m licence deal for KG013
South Korean biopharmaceutical company Celltrion has acquired exclusive global development and commercialisation rights to Kaigene's investigational monoclonal antibody, KG013, in…
-
Astellas and AI Proteins sign miniprotein therapeutics deal
AI Proteins has signed a research collaboration and licence agreement with Astellas Pharma’s affiliate Astellas Innovation Management for discovering and…
-
MSD’s Keytruda and Padcev combination receives EC approval
The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative treatment for…
-
FDA approves Cosette’s Evoxac oral solution for Sjögren’s disease
The US Food and Drug Administration (FDA) has granted approval for Cosette Pharmaceuticals’ Evoxac oral solution to treat dry mouth…
-
Sanofi and ScionxBio partner on mRNA therapies
Sanofi has signed a global licensing and strategic collaboration agreement with UK-based biotechnology company ScionxBio to develop long-acting messenger ribonucleic…
-
FDA approves Viatris’ Ryzumvi for adult presbyopia
The US Food and Drug Administration (FDA) has approved Viatris' Ryzumvi (phentolamine ophthalmic solution 0.75%) to treat presbyopia in adults.…